Jagsonpal Pharmaceuticals financials

·Pharma & HealthChart ›
Latest results Q2 FY27 · Jul–Sep 2026
Revenue
₹81.4cr+9.3% on Q2 FY26
Net profit
₹12.6cr+0.1% on Q2 FY26
EBITDA margin
20.6%−1.5 pts on Q2 FY26
EPS
₹1.91+1.6% on Q2 FY26

Quarterly results

Every quarter ›
₹ croreQ2 FY27Q2 FY26Change
Revenue81.474.5+9.3%
EBITDA16.816.4+2.0%
EBITDA margin20.6%22.1%−1.5 pts
Profit before tax16.816.8+0.1%
Net profit12.612.6+0.1%
EPS₹1.91₹1.88+1.6%

Over time

Q2 FY27 · Jul–Sep 2026latest
Revenue₹81.4 crNet profit₹12.6 crNet margin15.5%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
1,547————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
19.110.011.212.811.1
1,528————
301287269209237
—+6.9%+28.8%−11.8%—
61.458.151.123.134.2
20.4%20.2%19.0%11.1%14.4%
52.948.642.921.432.9
45.543.155.422.526.7
15.1%15.0%20.6%10.8%11.3%
₹6.79₹6.43₹8.27₹3.35₹3.99
—−22.2%+146.5%−15.9%—
—46.855.335.240.1
—0.0−0.3−0.2−0.3
46.846.855.034.939.8
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

JAGSNPHARM₹230.96

Jagsonpal Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersAMRUTANJANNGLFINESYNCOMFHESTERBIOSIGACHILINCOLNWINDLASMcap ₹1,547 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————1,546.6
- Cash, Equiv & ST Investments11.112.811.210.019.1
Enterprise Value————1,527.5
Revenue236.7208.7268.7287.2300.8
Growth %, YoY—-11.8+28.8+6.9—
EBITDA34.223.151.158.161.4
Margin %14.4311.0519.0120.2220.43
EBIT32.921.442.948.652.9
Net Income26.722.555.443.145.5
Margin %11.2910.7620.6015.0015.13
EPS, Adj (current shares)3.993.358.276.436.79
Growth %, YoY—-15.9+146.5-22.2—
Cash from Operations40.135.255.346.8—
Capital Expenditures-0.3-0.2-0.3-0.0—
Free Cash Flow39.834.955.046.846.8
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Jagsonpal Pharmaceuticals financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Jagsonpal Pharmaceuticals (NSE: JAGSNPHARM) had a market capitalisation of ₹1,479 crore at the 29 October 2026 close (₹221.94 a share), a PE ratio of 32.5 on the last four quarters' profit and a price-to-book ratio of 6.07. In FY26 its consolidated net profit was ₹43.1 crore on revenue of ₹287 crore; in Q2 FY27 (July–September 2026) it was ₹12.6 crore, up 0.1% year on year. It had no borrowings on 30 September 2026. Promoters held 68.81% of the shares on 30 September 2026.

Share price used
₹221.94 · 29 October 2026 close
Latest balance sheet
30 September 2026
Shareholding pattern
30 September 2026

Jagsonpal Pharmaceuticals at a glance · consolidated

Market cap
₹1,479 Crat ₹221.94 · 29 Oct close
PE ratio (last 4 quarters)
32.534.3 on FY26 profit
Price to book (PB)
6.07book value ₹36.59 a share
ROE (FY26)
16.7%−9.2 pts vs FY25ROCE 18.0%
Debt to equity
0.00net cash ₹114 Cr
Promoter holding
68.81%−0.2 pts vs 30 Jun 202630 September 2026
Dividend yield
1.80%₹4 a share in 12 months
Net worth
₹244 Cr−3.6% vs 30 Sep 202530 September 2026
Free cash flow (FY26)
₹46.8 Cr−14.8% vs FY25

Questions

What is the Jagsonpal Pharmaceuticals PE ratio today?

Jagsonpal Pharmaceuticals' PE ratio is 32.5 at the 29 October 2026 close (₹221.94 a share): a market capitalisation of ₹1,479 crore divided by consolidated net profit of ₹45.5 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit (₹43.1 crore) it is 34.3.

What is the Jagsonpal Pharmaceuticals PB ratio (price to book value)?

Jagsonpal Pharmaceuticals' price-to-book (PB) ratio is 6.07 at the 29 October 2026 close: a market capitalisation of ₹1,479 crore divided by shareholders' equity (book value) of ₹244 crore on 30 September 2026. That is a book value of ₹36.59 per share against a share price of ₹221.94.

What is the Jagsonpal Pharmaceuticals net worth?

Jagsonpal Pharmaceuticals' net worth — shareholders' equity in its consolidated balance sheet — was ₹244 crore on 30 September 2026, down 3.6% from ₹253 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹1,479 crore at the 29 October 2026 close.

What is the Jagsonpal Pharmaceuticals market cap?

Jagsonpal Pharmaceuticals' market capitalisation was ₹1,479 crore at the 29 October 2026 close: 6.66 crore shares at ₹221.94 each.

Is Jagsonpal Pharmaceuticals debt free?

Yes. Jagsonpal Pharmaceuticals had no borrowings on 30 September 2026 (consolidated balance sheet), and it held ₹114 crore of cash, bank balances and current investments.

What is the Jagsonpal Pharmaceuticals EPS?

Jagsonpal Pharmaceuticals' basic earnings per share (EPS) were ₹6.40 in FY26, against ₹8.26 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹6.83.

What is the Jagsonpal Pharmaceuticals debt to equity ratio?

Jagsonpal Pharmaceuticals' debt-to-equity ratio was 0.00 on 30 September 2026: no borrowings against total equity of ₹244 crore. A year earlier, on 30 September 2025, it was 0.00.

What is the Jagsonpal Pharmaceuticals book value per share?

Jagsonpal Pharmaceuticals' book value per share was ₹36.59 on 30 September 2026: shareholders' equity of ₹244 crore divided by the 6.66 crore shares in issue, down 3.6% from ₹37.94 a year earlier. The share price at the 29 October 2026 close was ₹221.94.

What is the Jagsonpal Pharmaceuticals dividend yield?

Jagsonpal Pharmaceuticals' dividend yield is 1.80% at the 29 October 2026 close: dividends of ₹4 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹221.94. They were ₹4 on 4 September 2026.

What is the Jagsonpal Pharmaceuticals ROE and ROCE?

In FY26, Jagsonpal Pharmaceuticals' return on equity (ROE) was 16.7% and its return on capital employed (ROCE) was 18.0%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 25.9% and ROCE 19.1%.

What is the Jagsonpal Pharmaceuticals promoter holding?

Promoters held 68.81% of Jagsonpal Pharmaceuticals on 30 September 2026, down 0.24 percentage points from 69.05% the previous quarter and up 1.27 percentage points from 67.54% a year earlier, according to the shareholding pattern filed with NSE.

What is the Jagsonpal Pharmaceuticals shareholding pattern?

On 30 September 2026, Jagsonpal Pharmaceuticals' shares were held by promoters 68.81%, foreign portfolio investors (FII/FPI) 2.14%, domestic institutions (DII) 1.65% (including mutual funds at 0.00%) and retail and other non-institutional investors 27.40%. Over the year, FII holding was up 0.02 percentage points from 2.12% and DII holding was up 1.56 percentage points from 0.09%.

What is the Jagsonpal Pharmaceuticals dividend in 2026 and its record date?

In 2026, Jagsonpal Pharmaceuticals has declared one dividend: ₹4 with record date 4 September 2026.

What is the Jagsonpal Pharmaceuticals free cash flow?

In FY26, Jagsonpal Pharmaceuticals generated ₹46.8 crore of cash from operations and spent ₹0 lakh on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹46.8 crore. In FY25 it was ₹55 crore.

What are the Jagsonpal Pharmaceuticals latest quarterly results?

Jagsonpal Pharmaceuticals' latest results are for Q2 FY27 (July–September 2026), filed on 28 October 2026: consolidated net profit ₹12.6 crore, up 0.1% from ₹12.6 crore in Q2 FY26; revenue from operations ₹81.4 crore, up 9.3% year on year.

What is the Jagsonpal Pharmaceuticals revenue and profit in FY26?

In FY26 (April 2025–March 2026), Jagsonpal Pharmaceuticals' consolidated net profit was ₹43.1 crore, down 22.2% from ₹55.4 crore in FY25, on revenue from operations of ₹287 crore (up 6.9%). Over three years, from FY23, net profit was up 61.2%.

When are the Jagsonpal Pharmaceuticals next results?

Jagsonpal Pharmaceuticals has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.

How does the Jagsonpal Pharmaceuticals PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit, Jagsonpal Pharmaceuticals' PE ratio is 34.3, the highest of the three: Amrutanjan Health Care 24.6 and NGL Fine-Chem 33.5, a peer average of 29.1. Each is the company's market capitalisation at that price divided by its FY26 net profit.

How does Jagsonpal Pharmaceuticals compare with its peers?

On FY26 consolidated figures, against Amrutanjan Health Care and NGL Fine-Chem: Jagsonpal Pharmaceuticals' operating margin of 16.9% is the highest of the three (Amrutanjan Health Care 13.8%, NGL Fine-Chem 10.6%; peer average 12.2%); its return on equity of 16.7% is the highest of the three (Amrutanjan Health Care 16.6%, NGL Fine-Chem 15.7%; peer average 16.2%); its revenue growth over three years of 6.7% a year is the lowest of the three (Amrutanjan Health Care 9.8% a year, NGL Fine-Chem 21.7% a year; peer average 15.7% a year).

Jagsonpal Pharmaceuticals vs Amrutanjan Health Care: how do they compare?

In FY26, Jagsonpal Pharmaceuticals earned net profit of ₹43.1 crore on revenue of ₹287 crore, against ₹57.9 crore on ₹503 crore for Amrutanjan Health Care. Jagsonpal Pharmaceuticals' operating margin was 16.9% (Amrutanjan Health Care 13.8%) and its return on equity 16.7% (Amrutanjan Health Care 16.6%). At the 29 October 2026 close, Jagsonpal Pharmaceuticals' market capitalisation was ₹1,479 crore against ₹1,426 crore for Amrutanjan Health Care, and its PE ratio on FY26 profit 34.3 against 24.6.

Where do these Jagsonpal Pharmaceuticals figures come from?

From Jagsonpal Pharmaceuticals' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.